372 related articles for article (PubMed ID: 32075391)
21. An evidence-based guideline on the application of molecular testing in the diagnosis, prediction of prognosis, and selection of therapy in non-GIST soft tissue sarcomas.
Yao X; Ghert M; Dickson BC; Popovic S; Purgina BM; Verma S; Werier J; Kandel RA
Cancer Treat Rev; 2020 Apr; 85():101987. PubMed ID: 32092619
[TBL] [Abstract][Full Text] [Related]
22. Current Concepts in Non-Gastrointestinal Stromal Tumor Soft Tissue Sarcomas: A Primer for Radiologists.
Baheti AD; Jagannathan JP; O'Neill A; Tirumani H; Tirumani SH
Korean J Radiol; 2017; 18(1):94-106. PubMed ID: 28096721
[TBL] [Abstract][Full Text] [Related]
23. TP53 in bone and soft tissue sarcomas.
Thoenen E; Curl A; Iwakuma T
Pharmacol Ther; 2019 Oct; 202():149-164. PubMed ID: 31276706
[TBL] [Abstract][Full Text] [Related]
24. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type?
Riedel RF
Semin Oncol; 2011 Oct; 38 Suppl 3():S30-42. PubMed ID: 22055970
[TBL] [Abstract][Full Text] [Related]
25. Lymphatic dissemination of bone and soft tissue sarcomas: a lymphographic investigation.
Tallroth K
Acta Radiol Suppl; 1976; 349():1-84. PubMed ID: 206099
[TBL] [Abstract][Full Text] [Related]
26. Molecular targeted therapy for advanced or metastatic soft tissue sarcoma.
Yuan J; Li X; Yu S
Cancer Control; 2021; 28():10732748211038424. PubMed ID: 34844463
[TBL] [Abstract][Full Text] [Related]
27. Dermatofibrosarcoma protuberans and gastrointestinal stromal tumor as models for targeted therapy in soft tissue sarcomas.
Koseła-Paterczyk H; Rutkowski P
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1107-1116. PubMed ID: 28988501
[TBL] [Abstract][Full Text] [Related]
28. Soft tissue sarcomas with non-EWS translocations: molecular genetic features and pathologic and clinical correlations.
Fisher C
Virchows Arch; 2010 Feb; 456(2):153-66. PubMed ID: 19396640
[TBL] [Abstract][Full Text] [Related]
29. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
30. Options for treating different soft tissue sarcoma subtypes.
Ray-Coquard I; Serre D; Reichardt P; Martín-Broto J; Bauer S
Future Oncol; 2018 May; 14(10s):25-49. PubMed ID: 29768052
[TBL] [Abstract][Full Text] [Related]
31. [Pleomorphic high-grade soft tissue sarcomas: is the subclassification up to date?].
Mechtersheimer G; Renner M; Penzel R; Schirmacher P
Pathologe; 2011 Feb; 32(1):47-56. PubMed ID: 21234572
[TBL] [Abstract][Full Text] [Related]
32. The clinical relevance of molecular genetics in soft tissue sarcomas.
Ordóñez JL; Osuna D; García-Domínguez DJ; Amaral AT; Otero-Motta AP; Mackintosh C; Sevillano MV; Barbado MV; Hernández T; de Alava E
Adv Anat Pathol; 2010 May; 17(3):162-81. PubMed ID: 20418671
[TBL] [Abstract][Full Text] [Related]
33. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.
Mertens F; Fletcher CD; Dal Cin P; De Wever I; Mandahl N; Mitelman F; Rosai J; Rydholm A; Sciot R; Tallini G; Van den Berghe H; Vanni R; Willén H
Genes Chromosomes Cancer; 1998 May; 22(1):16-25. PubMed ID: 9591630
[TBL] [Abstract][Full Text] [Related]
34. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
35. A current perspective on the role for molecular studies in soft tissue tumor pathology.
Dei Tos AP
Semin Diagn Pathol; 2013 Nov; 30(4):375-81. PubMed ID: 24342291
[TBL] [Abstract][Full Text] [Related]
36. From morphological to molecular diagnosis of soft tissue tumors.
Miettinen M
Adv Exp Med Biol; 2006; 587():99-113. PubMed ID: 17163160
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic considerations: how can we fine tune our approach to sarcoma?
Demicco EG; Lazar AJ
Semin Oncol; 2011 Oct; 38 Suppl 3():S3-18. PubMed ID: 22055969
[TBL] [Abstract][Full Text] [Related]
38. Current aspects of the pathology of soft tissue sarcomas.
Fisher C
Semin Radiat Oncol; 1999 Oct; 9(4):315-27. PubMed ID: 10516379
[TBL] [Abstract][Full Text] [Related]
39. Classification of pleomorphic sarcomas: where are we now?
Dei Tos AP
Histopathology; 2006 Jan; 48(1):51-62. PubMed ID: 16359537
[TBL] [Abstract][Full Text] [Related]
40. Clinical effect of molecular methods in sarcoma diagnosis (GENSARC): a prospective, multicentre, observational study.
Italiano A; Di Mauro I; Rapp J; Pierron G; Auger N; Alberti L; Chibon F; Escande F; Voegeli AC; Ghnassia JP; Keslair F; Laé M; Ranchère-Vince D; Terrier P; Baffert S; Coindre JM; Pedeutour F
Lancet Oncol; 2016 Apr; 17(4):532-538. PubMed ID: 26970672
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
